Newsfeeds - Spark Newswire

1 minute read

Terns Completes Part 1 Enrollment of AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

Today, 9:18 AM

Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy

TERN

5 minute read

66 Biggest Movers From Yesterday

By Lisa Levin

Today, 9:18 AM

Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019.

ABUS

2 minute read

Mid-Day Market Update: monday.com Jumps Following Strong Q2 Results; Kubient Shares Plunge

By Lisa Levin

Today, 9:18 AM

Midway through trading Tuesday, the Dow traded down 0.81% to 35,336.88 while the NASDAQ fell 0.89% to 14,661.86. The S&P also fell, dropping 0.65% to 4,450.54.

ATNM

4 minute read

48 Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

Today, 9:18 AM

Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares jumped 93% to $$8.10 after the company received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019.

ANY

1 minute read

Terns Pharmaceuticals Q2 EPS $(0.43) Up From $(33.09) YoY

By Bill Haddad

Today, 9:18 AM

Terns Pharmaceuticals (NASDAQ:TERN) reported quarterly losses of $(0.43) per share. This is a 98.7 percent increase over losses of $(33.09) per share from the same period last year.

TERN